

**Date:** November 02, 2021

**To,**  
**BSE Limited**  
Phiroze Jeejeebhoy Tower,  
Dalal Street, Mumbai – 400001.

Dear Sir/Madam,

**Sub.: Statement of Deviation in utilization of funds raised through Preferential Convertible warrant as required under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

With reference to the captioned subject matter, attached herewith the details of utilization of funds till 30<sup>th</sup> September, 2021.

Kindly acknowledge the receipt of the same.

**For Archit Organosys Limited**



**Kandarp Amin**  
**Chairman and Whole Time Director**

Encl: As above

## Statement of Deviation / Variation in utilization of funds raised

<b>Name of listed entity</b>	Archit Organosys Limited
<b>Mode of Fund Raising</b>	Preferential issue of Convertible Warrants
<b>Date of Raising Funds</b>	13/10/2020
<b>Amount Raised</b>	<p>Issued size of Rs. 550 lakh (55,00,000 number of warrants of Rs. 10 each). Upon application, total Rs. 137.5 lakh consisting of 55,00,000 warrant @ Rs 25% per share of Rs. 10/- each has received.</p> <p>Amount has received as per SEBI (ICDR) Regulations, 25% of issue price i.e. Rs. 2.5 per warrant has been received upon allotment of equity shares upon conversion of warrants.</p> <p>During last quarter, 20,00,000 warrants have been converted into equity shares on 31/05/2021 and balance 35,00,000 warrants have been converted into equity shares on 23/06/2021.</p>
<b>Report filed for Quarter ended</b>	<b>30<sup>th</sup> September, 2021</b>
<b>Monitoring Agency</b>	Not applicable
<b>Monitoring Agency Name, if applicable</b>	-
<b>Is there a Deviation / Variation in use of funds raised</b>	No
<b>If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders</b>	-
<b>If Yes, Date of shareholder Approval</b>	-
<b>Explanation for the Deviation / Variation</b>	-

<b>Comments of the Audit Committee after review</b>		-				
<b>Comments of the auditors, if any</b>		-				
<b>Objects for which funds have been raised and where there has been a deviation, in the following table</b>						
<b>Original Object</b>	<b>Modified Object, if any</b>	<b>Original Allocation</b>	<b>Modified allocation, if any</b>	<b>Funds Utilised</b>	<b>Amount of Deviation/ Variation for the quarter according to applicable object</b>	<b>Remarks if any</b>
The proceeds of the proposed issue will be utilized for any one or in combination with any one or more of the purposes such as to augment the fund for to augment the net worth of the Company and to form a capital base for business growth, to meet the long term fund requirements of the Company, to repay the debt of the Company for capital expenditure to be incurred for expansion and new product addition, to meet working capital requirements arose due to loss, to improve the capital structure and for general corporate purpose-	N.A	Issue Size: Rs. 550 Lakh  Amount received: Rs. 550 Lakh	N.A	Rs. 549.94 Lakh	N.A	Amount is received as per SEBI (ICDR) Regulations, 25% of issue price i.e. Rs. 2.5 per warrant has been received at the time of conversion of warrants.  During last quarter, the balance money has received and converted warrant into equity Share.

Date: 02/11/2021

*Kandarp Amin*

**Kandarp Amin  
Chairman and Whole Time  
Director**

